Sodium cation
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Sodium cation
- Accession Number
- DB14516
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Sodium cation (DB14516)
- Weight
- Average: 22.9898
Monoisotopic: 22.989769675 - Chemical Formula
- Na
- Synonyms
- Sodium (ion)
- Sodium ion
- sodium(1+)
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sodium cation. Aclidinium The therapeutic efficacy of Sodium cation can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sodium cation can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sodium cation is combined with Alloin. Almasilate The therapeutic efficacy of Sodium cation can be decreased when used in combination with Almasilate. Aluminium phosphate The therapeutic efficacy of Sodium cation can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Sodium cation can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Sodium cation can be decreased when used in combination with Amantadine. Amiloride The risk or severity of adverse effects can be increased when Amiloride is combined with Sodium cation. Amiodarone The therapeutic efficacy of Sodium cation can be decreased when used in combination with Amiodarone. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image NinePercent Sodium cation (90 g/1000g) Injection, solution Intravenous US Specialty Formulations LLC 2014-12-01 Not applicable US 
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- LYR4M0NH37
- CAS number
- 17341-25-2
- InChI Key
- FKNQFGJONOIPTF-UHFFFAOYSA-N
- InChI
- InChI=1S/Na/q+1
- IUPAC Name
- sodium(1+) ion
- SMILES
- [Na+]
References
- General References
- Not Available
- External Links
- PDB Entries
- 131d / 191d / 192d / 193l / 194l / 1a2c / 1a3d / 1a46 / 1a4w / 1a50 … show 9377 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Recruiting Prevention Cardiac Surgical Procedures 1 4 Recruiting Treatment Heart; Surgery, Heart, Functional Disturbance as Result 1 Not Available Completed Treatment Aortic Valve Disorder / Ischemia-Reperfusion Injury 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule, for solution Oral 7.5 mmol Injection, solution Intravenous 2.5 g/1000ml Suspension Oral 540 mg/5ml Tablet, chewable Oral 480 mg Injection, powder, for solution Intravenous 2 g/vial Injection, solution Intracardiac 5.1 mg/100mL Tablet, extended release Oral 500 MG Tablet, delayed release Oral 1000 mg Solution Oral 1.45 mmol/15mL Injection, solution Intravenous 90 g/1000g Injection, emulsion Intravenous 120 g Injection, emulsion Intravenous 160 g Injection, emulsion Intravenous 150 g Injection, emulsion Intravenous 225 g Injection, emulsion Intravenous 300 g Emulsion Intravenous 150 g Emulsion Intravenous 225 g Solution Intraperitoneal 510 mg/l Injection, emulsion Intravenous 3.66 g Injection, emulsion Intravenous 5.5 g Injection, emulsion Intravenous 7.33 g Injection, emulsion Intravenous 9.16 g Solution Intravenous 129.3 mEq/L Powder, for solution Oral 3.1 meq/100mL Solution Intravenous 12 g/L - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.77 ChemAxon pKa (Strongest Acidic) 3.09 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 0 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 0 Å2 ChemAxon Rotatable Bond Count 0 ChemAxon Refractivity 0 m3·mol-1 ChemAxon Polarizability 1.78 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created on July 12, 2018 10:35 / Updated on June 12, 2020 10:53